RAMM Pharma Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAMM.CN research report →
Companywww.rammpharma.com
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets.
- CEO
- Jackie Peter Burnett
- IPO
- 2019
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $1.79M
- P/E
- -0.21
- P/S
- 0.70
- P/B
- 0.37
- EV/EBITDA
- -0.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 6.78%
- Op Margin
- -168.55%
- Net Margin
- -337.31%
- ROE
- -96.79%
- ROIC
- -87.22%
Growth & Income
- Revenue
- $3.36M · -22.60%
- Net Income
- $-8,910,045 · 46.01%
- EPS
- $-0.07 · 46.71%
- Op Income
- $-4,517,501
- FCF YoY
- 73.80%
Performance & Tape
- 52W High
- $0.25
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.53
- Avg Volume
- 24.36K
Get TickerSpark's AI analysis on RAMM.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RAMM.CN Coverage
We haven't published any research on RAMM.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RAMM.CN Report →